As of May 29, 2025, Biofrontera AG (B8F.DE) reports a Net Margin of -1.14%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Biofrontera AG's Net Margin
Over recent years, Biofrontera AG's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2023-12-31 | -1.14% |
| 2022-12-31 | -171.60% |
| 2021-12-31 | 133.11% |
| 2020-12-31 | -42.92% |
| 2019-12-31 | -23.53% |
This steady improvement highlights how Biofrontera AG manages its overall profitability and cost control over time.
Comparing Biofrontera AG's Net Margin to Peers
To better understand Biofrontera AG's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Biofrontera AG (B8F.DE) | -1.14% |
| Circassia Group PLC (CIR.L) | 12.90% |
| Synthaverse SA (BML.WA) | 12.07% |
| Biosearch SA (BIO.MC) | 5.95% |
| Eurobio Scientific SA (ALERS.PA) | 3.72% |
| Paion AG (PA8.DE) | -1.74% |
Compared to its competitors, Biofrontera AG's Net Margin is among the highest compared to peers, suggesting strong overall cost management and pricing power.